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Abstract: Global trends in HIV infection demonstrate an overall increase in HIV prevalence and substantial declines in AIDS related
deaths largely attributable to the survival benefits of antiretroviral treatment. Sub-Saharan Africa carries a disproportionate burden of
HIV, accounting for more than 70% of the global burden of infection. Success in HIV prevention in sub-Saharan Africa has the
potential to impact on the global burden of HIV. Notwithstanding substantial progress in scaling up antiretroviral therapy (ART),
sub-Saharan Africa accounted for 74% of the 1.5 million AIDS related deaths in 2013.
Of the estimated 6000 new infections that occur globally each day, two out of three are in sub-Saharan Africa with young women
continuing to bear a disproportionate burden. Adolescent girls and young women aged 15-24 years have up to eight fold higher rates
of HIV infection compared to their male peers. There remains a gap in women initiated HIV prevention technologies especially for
women who are unable to negotiate the current HIV prevention options of abstinence, behavior change, condoms and medical male
circumcision or early treatment initiation in their relationships.
The possibility of an AIDS free generation cannot be realized unless we are able to prevent HIV infection in young women. This
review will focus on the epidemiology of HIV infection in sub-Saharan Africa, key drivers of the continued high incidence, mortality
rates and priorities for altering current epidemic trajectory in the region. Strategies for optimizing the use of existing and increasingly
limited resources are included.
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INTRODUCTION
With more than thirty years of the HIV epidemic, there is still no cure or an effective vaccine, however, there have
been major advances in treating HIV [1 - 3] as the availability and rapid scale up of antiretroviral therapy (ART) has
transformed what was inevitably a fatal disease to a chronic, manageable condition leading to notable declines in the
worldwide  rates  of  AIDS  related  deaths  and  new  infections.  Whilst  research  into  HIV  vaccines  and  vaginal
microbicides continue, major breakthroughs in the prevention of HIV include voluntary male medical circumcision [4 -
6] and antiretrovirals for the prevention of mother to child transmission [7], for preventing transmission [8] and as pre-
exposure prophylaxis [8] has been achieved [9, 10].
Furthermore,  focusing  on  high  transmission  areas  and  key  populations,  together  with  the  implementation  of
evidence-based combination prevention strategies has the ability to substantially reduce HIV transmissions and achieve
epidemic control,  potentially transforming the pandemic to low level endemic epidemics [11].  Notwithstanding the
major advances in the delivery of HIV prevention and treatment to attain epidemic control, initiatives to prevent sexual
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transmission  of  HIV,  indeed  the  major  mode  of  transmission  in  sub-Saharan  Africa  remains  a  challenge  to  the
possibility of an AIDS free generation.
ESTIMATES OF HIV IN SUB-SAHARAN AFRICA
In 2013 an estimated 35.0 [33.2-37.2, (range around estimate)] million people were living with HIV worldwide.
Sub-Saharan Africa is home to only 12% of the global population, yet accounts for 71% of the global burden of HIV
infection. Ten countries, mostly in southern and eastern Africa, viz. South Africa (25%), Nigeria (13%), Mozambique
(6%), Uganda (6%), Tanzania (6%), Zambia (4%), Zimbabwe (6%), Kenya (6%), Malawi (4%) and Ethiopia (3%),
account for almost 80% of all people living with HIV [12].
The trends in new HIV infections across countries in sub-Saharan Africa have shown a decline by more than 33%
from an estimated 2.2 (2.1-2.3) million in 2005 to 1.5 (1.3-1.6) million in 2013, but remain high. The scale up and
widespread  coverage  of  ART has  led  to  substantial  declines  in  new HIV infections.  For  example,  HIV uninfected
individuals living in a community with high ART coverage (30 to 40% of all HIV-infected individuals on ART) were
38% less likely to acquire HIV than those living in communities where ART coverage was low (<10% of all HIV-
infected  individuals  on  ART) [13].  Despite  these  declines,  HIV incidence  rates  remain  unacceptably  high with  the
largest number of new infections coming from South Africa (23%), Nigeria (15%), Uganda (10%), Mozambique (8%)
and Kenya (7%) [12]. The epidemics in Botswana, Namibia and Zambia appear to be declining, whilst the epidemics in
Lesotho, Mozambique and Swaziland seem to be plateauing [12].
In sub-Saharan Africa, the main mode of HIV transmission is through heterosexual sex with a concomitant epidemic
in children through vertical transmission. As such, women are disproportionately affected accounting for 58% of the
total number of people living with HIV, have the highest number of children living with HIV and the highest number of
AIDS related deaths.
With  increasing  access  to  ART,  the  number  of  AIDS related  deaths  have  steadily  declined  and  in  sub-Saharan
Africa these decreased by 39% between 2005 and 2013 [12]. In South Africa alone the decline was 51% whereas in
Ethiopia it was 37% and in Kenya it was 32%. Several empiric studies from South Africa, Uganda, Tanzania, Rwanda
and Malawi have demonstrated that the impact of modest ART coverage at CD4 cell counts ranging from <200 to 500
cell per µl resulted in significant declines in mortality with life expectancy increasing by an additional 10 years [14 -
21]. These studies provide evidence on the benefits of early ART initiation to HIV positive individuals.
Despite these benefits of ART, in 2013 the region still accounted for 74% of deaths from AIDS related illnesses.
Whilst the achievements of the Millennium Development Goals (MDG) specifically “to halt and begin to reverse the
HIV epidemic” have begun to show a downward trend in HIV infection, it is critical that the Sustainable Development
Goals  (SDGs)  of  2015  dedicated  to  improving  the  well  being  of  present  and  future  generations  have  far  reaching,
profound and sustained impact on health and increases in life expectancy by reaching out to HIV positive individuals
irrespective of CD4 cell counts [2, 22, 23].
PRIORITY POPULATIONS FOR HIV PREVENTION
Globally, 15% of women living with HIV are aged 15-24 years, of whom 80% live in sub-Saharan Africa. In this
region where just over 70% of all new HIV infections occur, young women bear a disproportionate burden of HIV
infection. Not only do young women aged 15-24 years have HIV rates higher than their male peers, they acquire HIV
infection 5-7 years earlier than their male peers. Although there are some declining trends in the 15-24 year age group,
HIV prevalence is consistently higher among young women compared to young men throughout eastern and southern
Africa [12] (Table 1).
The disproportionately high HIV prevalence throughout the region suggest the lack of appropriate interventions to
protect  young  women  and  to  meet  their  sexual  and  reproductive  health  needs  as  they  prepare  for  adulthood  [12].
Furthermore, marked male female differences in sexual debut, age disparate sex, transactional sex, multiple partners and
partner  concurrency,  low condom use  and  sexually  transmitted  infections  contribute  to  adolescent  girls  and  young
women’s vulnerability to HIV [25 - 31].
In the region, there is a paucity of research in marginalized groups such as men who have sex with men, people who
inject drugs and sex workers, however, emerging data suggests that HIV prevalence is significantly higher in these
groups than in the general population [32]. Studies from South Africa and Kenya show that HIV prevalence was almost
three fold higher in men who had sex with men than in men who had sex with women only [33, 34]. Similarly, HIV
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incidence rates have also been three to four fold higher at 35.2 [95% confidence interval (CI) 23.8-52.1] per 100 person
years (py) among men who have sex with men only, compared to 5.8 (95% CI 4.2-7.9) per 100 py among men who
have sex with men and women [34].
The data on people who inject drugs are even sparser, however, studies from Kenya and Tanzania show a similar
high HIV prevalence of 36% and 35% respectively [35, 36] compared to the 6.0% and 5.0% in the general population
[12]. Injecting drug use is a growing concern across the region compounded by reports of high risk sexual behaviors in
these  individuals.  The  absence  of  harm reduction  programs and  persistent  high  risk  behaviors  has  implications  for
transmission of HIV.
Sex work has been the key driver of the epidemic in the region and the burden of HIV remains disproportionately
high amongst female sex workers. Even in countries with generalized epidemics, HIV prevalence is at least two fold
higher in this group than in the general population and the pooled HIV prevalence among female sex workers in sub-
Saharan Africa was 30.7% (95% CI 30.2-31.3) and the odds ratio for infection was 11.6 (95% CI 9.1-14.8) [37]. Whilst
the number of life time sex partners, risky sex acts or behavioral practices impact on HIV acquisition, sex workers
within sexual networks play a role in sustaining transmission.
Despite the impact of combination prevention interventions that target high risk marginalized populations, the major
challenges in the region are the discriminatory environments and in-country legislation that not only sustain, but fuel the
epidemics resulting in extraordinarily high prevalence [38]. Major challenges exist in maintaining the declining rates of
HIV infections. It is imperative that structural, behavioral and biomedical interventions are evidence and rights based,
are non-discriminatory and gender transformative [38].  Furthermore,  the programs should aim to decriminalize sex
work, men who have sex with men and reduce intimate partner violence [39, 40] as these impact on HIV prevention
efforts.  Ideally,  access  to  comprehensive  sexual  reproductive  health  services  for  HIV  prevention  should  focus  on
maximizing on coverage of interventions [12].
Table  1.  HIV  prevalence  (%)  among  people  15-24  years  old,  by  sex  in  selected  sub-Saharan  African  countries  in  2013.





South Africa 13.1 4.0 3.3
Swaziland 12.4 7.1 1.7
Lesotho 10.5 5.8 1.8
Zimbabwe 6.6 4.1 1.6
Mozambique 6.1 2.7 2.3
Botswana 6.0 3.5 1.7
Zambia 4.5 4.4 1.0
Uganda 4.2 2.4 1.8
Malawi 3.8 2.4 1.6
Kenya 2.8 1.7 1.6
Tanzania 2.2 1.4 1.6
Central African Republic 1.5 0.9 1.7
Congo 1.2 0.7 1.7
Rwanda 1.2 0.9 1.3
HIV PREVENTION STRATEGIES
Intensifying  prevention  activities  requires  a  thorough  understanding  of  the  HIV epidemic  typologies,  modes  of
transmission and populations affected as these inform the extent to which evidence based modalities can be customized
and combined to substantially reduce HIV transmission which is critical in continuing the path to altering epidemic
trajectory [41 - 43].
The  evolving  epidemic  has  been  characterized  into  several  typologies  to  capture  the  dominant  characteristic  at
regional and or country level. However, a key feature of the epidemic is variation in disease burden not only across
population and countries but across districts and sub districts. Countries characterized as having low-level epidemics,
where adult HIV prevalence has not spread to significant levels in the general population nationally, nor in any sub-
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population, suggests that sexual networks of risk are diffuse and driven by low levels of partner change or concurrent
sexual relationships or that the virus may have been recently introduced.
In such settings, information on the most vulnerable and at risk populations is needed to understand risk behaviors,
social sexual networks and factors such as rates of sexually transmitted infections (STIs) that could potentially impact
on  the  spread  of  HIV.  Many West  African  countries  such  as  Benin  (1.1%),  Burkina  Faso  (0.9%),  Gambia  (1.2%),
Ghana (1.3%), Guinea (1.7%), Liberia (1.1%), Mali (0,9%), Niger (0.4%), Senegal (0.5%), and Sierra Leone (1.6%)
experience low level epidemics [12, 44]. Thus, prevention planning should track the epidemic and entail knowledge of
HIV trends.
In concentrated epidemic settings, HIV has spread rapidly in one or more populations but is not well established in
the general population. Adult HIV prevalence is high enough in one or more sub-populations, such as men who have
sex with men (MSM), people who inject drugs (PWID) or sex workers and their clients who maintain the epidemic in
this  sub-population,  but  the virus  has  not  spread in  the general  population.  In  several  countries,  HIV prevalence is
nearly  20  times  higher  amongst  high  risk  sub-populations  such  as  MSM  and  sex  workers  compared  to  adult  HIV
prevalence in the general population.
In Burundi, HIV prevalence in sex workers is 26.5% compared to 1.0% in the general adult population, whilst in
Côte d'Ivoire amongst MSM and sex workers, HIV prevalence is 18.8% and 28.7% respectively compared to 2.7% in
the general adult population [12, 23]. To prevent epidemics expanding to the general population, HIV prevention efforts
should focus on understanding the dynamics of HIV transmission, tracking the size and course of the epidemic and
prioritizing and intensifying interventions in affected sub-populations.
In generalized epidemic settings, HIV prevalence is well established in pregnant women attending antenatal clinics,
indicating  that  the  presence  of  HIV  among  the  general  population  is  sufficient  for  sexual  networking  to  drive  the
epidemic.  Multiple partner  relationships giving rise to sexual  networks intensify HIV transmission and account for
majority of infections. Importantly, the behaviors of most at risk populations through longer term multiple concurrent
relationships sustain HIV transmission in the general population [42].
In countries such as Kenya (6.0%), Uganda (7.4%) and Tanzania (5.0%) [12], the adult HIV prevalence is in excess
of 5% rendering the majority of sexually active people to be at an elevated risk of acquiring HIV. Thus, prevention
efforts must focus on broad social movements that contribute to safer sex behaviors and extend to those in the general
population with increased vulnerability to HIV, especially young people.
In generalized, hyper endemic epidemic settings HIV prevalence exceeds 15% in the adult population [42]. With
more than 50% of women and girls  living with HIV, risk factors for  HIV acquisition are complex and diverse and
driven by behaviors such as early sexual debut,  high levels of longer term multiple concurrent sexual partnerships,
gender based violence, intergenerational sex, inconsistent condom use with casual rather than with longer term partners,
low acceptability of condom use in cohabiting couples and biological co factors such as low levels of male circumcision
and the presence of STIs, including viral infections.
In such settings, high levels of HIV related stigma, gender based violence and sexual coercion fuel the spread of
HIV in the general population, leading to excessively high prevalence [45, 46]. Countries such as Botswana (21.9%),
Lesotho (22.9%), South Africa (19.1%), Swaziland (27.4%) and Zimbabwe (15.0%) have hyper endemic epidemics and
similarly countries such as Malawi (10.3%), Mozambique (10.8%), Namibia (14.3%) and Zambia (12.5%) [12] have
high HIV prevalence requiring exceptional effort  and resources in the investment of communities to change sexual
behaviors.
A  unique  feature  of  the  generalized  epidemic  typology  in  this  region  is  the  occurrence  of  concentrated  sub
epidemics  in “hidden” high risk populations such as men who have sex with men, people who inject drugs and sex
workers. These groups are at an increased risk of infection, yet are less likely to access HIV prevention and treatment
services because of the pervasive stigma and discrimination against these groups [38, 46]. A more recent concern has
been the role of HIV super infection, which occurs when an infected individual is infected again, by another variant.
Super  infection  leads  to  a  spike  in  viral  load  and  individuals  can  transmit  either  variant  or  a  recombinant  form to
partners [47, 48].
Understanding HIV epidemic typologies has been central to the design of prevention programs, however a more in-
depth and nuanced understanding of HIV transmission is needed to direct interventions. Recent efforts to reduce sexual
transmission of HIV have made progress and strategies from recent evidence based interventions are promising and
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should incrementally be tested and evaluated in populations at risk for HIV. To prevent the further spread of HIV, focus
on combination strategies and reaching the majority of sex workers, their clients, MSM and other high risk individuals
is key to altering epidemic trajectory [43].
NEWER TOOLS TO TARGET HIV PREVENTION
“Knowing  your  epidemic”  has  been  the  basis  and  opportunity  for  countries  to  critically  assess  and  match  the
prevention response to meet the priority needs [41, 42]. Whilst these have been useful as a national response and scaled
up towards attaining universal access to prevention and treatment including care and support for all, these have failed to
address  social  and  economic  factors  and  power  in  relationships.  These  relationships,  together  with  physiological
differences,  determine  to  a  great  extent  an  individual’s  risk  of  infection  and  their  ability  to  protect  themselves.
However, country level HIV data masks diverse, complex and heterogeneous epidemics at sub-national, regional and
district  level.  Furthermore,  as  new HIV infections  continue  one  or  more  sub-populations  of  virus  emerge  [47,  48]
resulting in the spread of HIV viral variants.
The complexity and heterogeneity of local epidemics evolve with localized differences, highlighting the importance
of “locations” and “populations” [49 - 51] as the overall country level HIV prevalence may mask the true complex
mosaic nature of the epidemic in relation to key risk factors and populations. As evidenced by district level prevalence
and geospatial mapping of HIV; South Africa, Nigeria, Mozambique, Burkina Faso and Malawi experience significant
variability with “hotspots” clustered around truck stops, main transport routes, sex work and further complicated by
migration and limited access to health care [49, 51 - 55].
Geospatial mapping is a novel approach that is being used to map HIV infections [51, 55] in order to understand
geographic variation of the HIV epidemic, its drivers, and for increasing the efficiency of targeted interventions in high
HIV burden, resource poor settings. Adding to this novel approach, phylogenetic analyses of HIV-1 viral sequences are
increasingly being applied to map HIV transmission links. The transmission links are important to understand dyadic
relationships, and to identify clusters or networks in communities. A combination of HIV phylogenetic analyses with
the relevant socio demographic and behavioral data provide powerful knowledge on patterns and dynamics of HIV
transmission networks across communities, which could guide HIV prevention and intervention strategies [56 - 58].
In  the  village  of  Mochudi,  Botswana,  a  high  proportion  of  Mochudi  unique  clusters  were  identified  among
sequences suggesting that the HIV epidemic in this community is dominated by locally circulating viral variants [56].
Meanwhile in Uganda, using locations of self reported sexual partners, approximately 39% of new viral transmissions
occurred within stable household partnerships, and that among those infected by extra household sexual partners, 62%
were  infected  by  sexual  partners  from  outside  their  community  [50].  These  data  provide  empirical  evidence  to
understand the dynamic heterogeneity of HIV which to a significant degree is often masked at a country level [49].
Whilst  there  are  ethical  challenges  in  identifying  who  is  infecting  who  and  understanding  sexual  networks
particularly in generalized epidemics, these data also highlight the importance of specific “locations” to understand the
drivers of heterogeneity within a country, so that prevention and treatment efforts can be tailored and implemented
within discreet and/or broader communities while targeting key populations and focusing on high transmission areas.
HIV PREVENTION INTERVENTIONS
The HIV prevention  field  has  evolved  rapidly  over  the  last  five  years.  Numerous  interventions  to  prevent  HIV
acquisition are available; however, these have not been implemented and utilized in relation to the magnitude of HIV
burden. Comprehensive and effective public health strategies include programming for behavior change, condom use,
HIV  testing  and  knowledge  of  HIV  status,  harm  reduction  efforts  for  injecting  substance  use,  medical  male
circumcision  and  provision  of  post  exposure  prophylaxis.
Whilst  the  combination  of  these  HIV prevention  packages  has  the  potential  to  prevent  more  than  90% of  HIV
transmission during vaginal and anal sexual intercourse, their use is mainly influenced by relationship type and heavily
influenced by the form of partnerships [59, 60]. For example condom use is generally highest in commercial sex work
and  lower  and  inconsistent  in  non  commercial  and  regular  partnerships  [61].  Studies  indicate  that  the  majority  of
women are generally unable to negotiate consistent male or female condom use which is largely dependent on male
partner co-operation.
Although increases in male condom distribution and use played a key role in declining HIV incidence during the
period  2000-2008  [62],  the  major  challenge  has  been  sustaining  consistent  condom  use  [63]  so  men  can  protect
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themselves and their partners. Similarly HIV counselling and testing (HCT) has been tested through several models [64
- 68] to enhance knowledge of HIV status, access HIV prevention and treatment programs and minimize stigma and
discrimination in association with HIV Although these innovative approaches and expansion of services have been
fundamental in promoting knowledge of HIV status to access treatment and promoting preventing onward transmission,
knowledge of HIV status remains low.
Results from three randomized controlled trials (RCTs) and modelling data have paved the way for large scale roll-
out  of  voluntary  medical  male  circumcision  (VMMC) as  an  important  intervention  by  engaging  men and reducing
heterosexually acquired HIV [4 - 6, 69]. Translating VMMC for public health benefit requires wide spread coverage to
over 80% with priority in the countries with high prevalence of HIV and low prevalence of VMMC.
Although  the  pace  and  uptake  of  VMMC  is  encouraging,  VMMC  prevalence  varies  with  Ethiopia  and  Kenya
reaching  57% and 63% respectively  of  the  coverage  target.  In  Lesotho,  Malawi,  Namibia,  Rwanda  and  Zimbabwe
where VMMC is stated to be a priority, coverage of adult VMMC is less than 10% [12]. These data suggest that for any
benefit  of  VMMC  to  be  realized,  coverage  must  be  scaled  up.  Improving  surgical  procedures  and  using  novel
approaches for recruitment for the safe delivery of high quality VMMC services would contribute to rapidly achieving
targets for public health benefit [70 - 73].
Several  RCTs  of  cervical  barrier,  diaphragm  and  non  antiretroviral  (ARV)  based  microbicides  when  applied
vaginally  have  failed  to  show  any  significant  benefit  in  preventing  HIV  acquisition  [74  -  80].  However,  recent
breakthroughs have been testing of ARV based vaginal microbicides, oral pre-exposure prophylaxis (PrEP) and early
ART initiation have transformed the HIV prevention agenda and provide hope in reducing the risk of acquiring HIV
(Table 2). The effectiveness of peri coital tenofovir gel in the CAPRISA 004 trial showed that women inserting one
dose of gel vaginally within 12 hours before sex and a second dose as soon as possible within 12 hours after sex and not
using more than two doses of gel in a 24 hours period, reduced the risk of HIV acquisition by 39% [81].
However, the effectiveness of daily or peri-coital vaginal application of tenofovir gel in the VOICE (Vaginal and
Oral interventions to Curb the Epidemic) [82] and the Follow-on African Consortium for Tenofovir Studies (FACTS)
001 trial respectively failed to demonstrate a protective effect [83]. Similarly, the FEM PrEP trial tested a daily single
oral dose of Truvada® which contain two ARV drugs: tenofovir disoproxilfumarate (TDF-300 mg) and emtricitabine
(FTC-200 mg) also failed to demonstrate the effectiveness of truvada in preventing HIV acquisition [84]. Whilst these
trials had no safety concerns, the major drawback was the lack of adherence and therefore the failure to demonstrate the
effectiveness of the study products.
Nevertheless, PrEP in high risk populations are promising biomedical HIV prevention interventions. In the iPrEx
(Pre-exposure  Prophylaxis  Initiative)  trial  in  MSMs,  a  daily  single  oral  dose  of  Truvada®  demonstrated  a  44%
protection against HIV acquisition. The Centers for Disease Control(CDC) PrEP Study (CDC TDF2) which tested a
daily single oral dose of Truvada® among heterosexual men and women in Botswana showed a 62.2% reduction in HIV
acquisition [85]. In Uganda and Kenya, the protective effect of a single oral daily dose of TDFor Truvada® was 67%
and 75% respectively among sero-discordant men and women [86]. The most promising results come from the testing
of Truvada® as PrEP in the PROUD (Pragmatic Open-Label Randomised Trial of Pre-exposure Prophylaxis) [87] and
IPERGAY [88] studies which tested daily and “on demand” dosing strategy respectively and both studies showed an
86%  reduced  risk  of  HIV  [87,  88].  The  MTN-020-ASPIRE  Study  tested  a  silicone  elastomer  vaginal  matrix  ring
containing 25 mg of dapivirine inserted monthly in women between the ages of  18 and 45 years in Malawi,  South
Africa, Uganda and Zimbabwe. HIV incidence was 27% lower in women in the dapivirine compared to the placebo
group. In the modified analysis excluding data from two sites that had reduced rates of retention and adherence, HIV
incidence in the dapivirine group was lower by 37%. In the post-hoc analysis, higher rates of protection were observed
among women over the age of 21 years (56%) but not among those younger than 21 years (-27%) and this difference
correlated with reduced adherence to study product [89]. The independent Data Safety Monitoring Board of IPM 027
(Ring-004) study, recommended the analysis of data prior to study completion. In this trial the dapivirine vaginal ring
reduced the risk of HIV-1 infection by 30.7% relative to placebo in women 18 to 45 years of age from South Africa and
Uganda with efficacy of 37.5% in women older than 21 years [90]. These results provide renewed hope for women
initiated methods, whilst clinical trials on newer ARVs with alternate delivery mechanisms are currently underway and
the role of potent broadly neutralizing monoclonal antibodies are being explored as newer HIV prevention interventions
[24, 91].
These interventions would fill an important gap as HIV prevention options for young women and impact on new
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HIV infections  [24].  The major  challenge of  these promising interventions  is  that  they are  not  yet  licensed in  sub-
Saharan Africa for public sector use. Whilst vaginal microbicides and oral PrEP are urgently needed as behaviors are
difficult to modify, effect and sustain, their effectiveness is largely dependent on risk perception, uptake of interventions
and adherence to interventions [10], further complicated by genital inflammation with increased concentrations of HIV
target cell recruiting chemokines and a genital inflammatory profile contributing to HIV acquisition [92].
Recent research has shown that providing ART early at higher CD4 cell counts as opposed to delaying treatment
significantly reduces heterosexual transmission and prevent's 96% of transmissions [8]. These data are consistent with
data from several cohort studies and with ecological studies which showed a >10% reduction in HIV incidence at a
population level for every 10% increase in ART coverage of HIV positive individuals living in the same geographic
area [13, 15, 96]. These findings provide compelling evidence to the importance of viral load as a key predictor of HIV
transmission. Furthermore, adding VMMC, behaviour change communication, early ART and preexposure prophylaxis
could achieve greater effect in reaching the goals of epidemic control.
More importantly, early ART has been supported through the contemporary WHO 2014 guidelines as an effective
tool to reduce HIV transmission rates.
Table 2. Randomised clinical trial evidence for preventing sexual transmission of HIV (adapted from [93]).
Randomised Clinical Trials Effect size (95%CI) Reference
 Vaginal Microbicide
CAPRISA 004 - peri-coital tenofovir gel
(Women in South Africa)
39% (6; 60) [81]
MTN003/VOICE - daily tenofovir gel
(Women in South Africa, Uganda, Zimbabwe)
15% (-21; 40) [82]
FACTS 001- peri-coital tenofovir gel
(Women in South Africa)
0% (-40; 30) [83]
MTN-020-ASPIRE -monthly vaginal ring containing dapivirine
(Women in Malawi, South Africa, Uganda, and Zimbabwe)
27% (1; 46) [89]
IPM 027/Ring Study monthly vaginal ring containing dapivirine
(Women in South Africa and Uganda)
30.7% (0.90-51.5) [90]
 Oral Pre-exposure prophylaxis
IPERGAY - on demand emtricitabine and tenofovir*
(Men who have sex with men in France)
86% (39; 99) [88]
PROUD - daily emtricitabine and tenofovir
(Men who have sex with men in United Kingdom)
86% (62; 96) [87]
Partners PrEP - daily emtricitabine and tenofovir
(HIV serodiscordant couples in Kenya, Uganda)
75% (55; 87) [86]
Partners PrEP - daily tenofovir
(HIV serodiscordant couples in Kenya, Uganda)
67% (44; 81) [86]
TDF2 - daily emtricitabine and tenofovir
(Heterosexuals men and women in Botswana)
62% (22; 84) [85]
iPrEx - daily emtricitabine and tenofovir
(Men who have sex with men in America’s, Thailand, South Africa)
44% (15; 63) [94]
FEMPrEP - daily emtricitabine and tenofovir
(Women in Kenya, South Africa, Tanzania)
6% (-52; 41) [84]
MTN003/VOICE - daily emtricitabine and tenofovir
(Women in South Africa, Uganda, Zimbabwe)
4% (-49; 27) [82]
MTN003/VOICE - daily tenofovir
(Women in South Africa, Uganda, Zimbabwe)
-49% (-129; 3) [82]
 Other
HPTN 052- Antiretroviral therapy as prevention
 (HIV serodiscordant couples in Africa, Asia, America)
96% (73; 99) [8]
Medical Male circumcision






(Men and women in Mwanza, Tanzania)
42% (21; 58) [95]
*emtricitabine and tenofovir - Truvada®
Although  high  coverage  of  early  or  universal  ART  with  VMMC,  behaviour  change  communication  and  pre-
exposure prophylaxis could achieve greater effect to reach the goal of epidemic control and virtually eliminate HIV
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transmission [9, 11], population-based RCTs are currently ongoing to determine the effectiveness of these regimens in
reducing the HIV incidence [97].
ACHIEVING UNIVERSAL ACCESS TO ANTIRETROVIRAL THERAPY PROGRAMS
Effective ART first introduced in 1996, led to dramatic reductions in morbidity and mortality [20]. There has been a
parallel increase in the number of pregnant women receiving ART for the prevention of mother to child transmission of
HIV and significantly more women and children are receiving ART [98]. In sub-Saharan Africa, AIDS related deaths
overall  have declined by 39% in the period 2005 to 2013 with dramatic declines in Rwanda (76%),  Eritrea (67%),
Ethiopia (63%), Kenya (60%), Botswana (58%), Burkina Faso (58%), Zimbabwe (57%), Malawi (51%), South Africa
(48%) and Tanzania (44%) attributable to the rapid increase in the number of people on ART.
Most countries have progressed with scaling-up ART provision and with a commitment to increase the numbers
over the next several years. In South Africa alone over 2.0 of the 6.4 million HIV positive individuals are on ART,
making it one of the largest programs in the world [99, 100]. Similarly Botswana, Namibia and Rwanda have made
remarkable progress with more than 80% coverage of eligible individuals on ART based on WHO 2010 guidelines,
whilst several other countries like Zambia and Swaziland are steadily increasing ART initiation.
Approximately 75% of all people receiving ART live in sub-Saharan Africa, yet many more are in need of and are
eligible for ART; and as such promising results  from the INSIGHT START trial  [3] of initiating ART in the early
asymptomatic  stage  at  CD4 cell  counts  of  >500 and the  TEMPRANO ANRS trial  [1]  of  early  ART and including
isoniazid preventive therapy offer significant benefits in further reducing AIDS related severe illness including death.
Notwithstanding  the  success  of  the  region  as  a  whole  in  scaling  up  ART,  this  masks  significant  in  country
variability  with  some  countries  e.g.  Botswana,  South  Africa,  Zambia,  Zimbabwe  and  Malawi  are  providing  better
treatment access compared to countries such as Nigeria and Central Africa Republic where less than 25% of the adult
population have access to treatment [12]. The variability in treatment access remains a challenge and may potentially
reverse the gains made thus far. The major milestones of ART provision aiming for maximum coverage through early
or universal ART is rapidly advancing in many countries [101]. However, some countries have not met their targets
highlighting  the  complex  challenges  of  patient  populations  that  remain  under-served  and  undermining  the  parallel
prevention efforts. It is hoped that strengthening of health systems, reducing costs, improving and simplifying treatment
are  more  likely  to  improve  adherence  to  drug  regimens  with  better  chances  for  long  term  survival.  New  ART
formulations  can  also  help  address  some  of  the  current  challenges  including  funding  constraints.
HIV PREVENTION CONTINUUM
Current models and measures of HIV care include testing and diagnosis, linkage and enrolment into care, initiation
of ART, retention in care and achieving viral suppression at HIV RNA <1000 copies /ml [102]. This approach has been
successful for individual benefit in reducing morbidity and mortality. However, the HPTN 052 trial which showed a
96% reduction in the number of linked HIV transmissions due to early ART initiation illustrates the importance of this
strategy to achieve viral suppression and onward transmission [8].
Whilst a few individuals with HIV are aware of their infection, the majority have never tested to know if they are
infected. Comprehensive HIV testing programs with either community centered or innovative approaches which include
self-testing would improve knowledge of HIV status. Furthermore, of the many individuals with HIV, less than half
receive  adequate  and  ongoing  treatment  and  less  than  a  quarter  of  those  on  ART  successfully  maintain  viral
suppression. Therefore undiagnosed HIV infection and inadequate viral suppression remain significant factors fueling
the epidemic and threatening epidemic control in sub-Saharan Africa.
The WHO recommendation of 2014 to offer treatment at CD4 cell count of 500 cells/mm³ or less provides almost
universal access to ART which, if implemented, could potentially be cost effective as many lives would be saved. It
provides hope for controlling the virus at the individual level decreasing mortality and importantly and at the public
health level decreasing HIV transmission. Thus, populations that are currently underserved would benefit from large
scale HIV testing, knowledge of HIV status, expediting early access to and adherence to treatment, mitigate stigma and
discrimination and realization of prevention benefits from early treatment initiation [97, 103 - 107].
KEY POINTS
Sub-Saharan  Africa  bears  the  highest  burden  of  HIV infection  globally.  Notwithstanding  success  in  a  growing
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number of countries with stabilized epidemics and or reductions in new HIV infections, the continued high burden of
new HIV infections in South Africa, Swaziland, Lesotho, Zimbabwe, Botswana, Mozambique, Namibia and Zambia
contribute to new infections globally.
It  is  imperative that  innovative models of delivery,  together with information and education on HCT, male and
female condoms and VMMC are expanded to maximize on the coverage of these existing cost effective interventions.
The rapid scale-up of targeted primary prevention and testing and treatment services for high risk individuals such
MSMs, PWID and sex workers are needed to prevent further transmission.
A geospatial prioritization with targeted HIV prevention services within and between countries could reduce the
burden of HIV in sub-Saharan Africa and impact on the global burden of HIV. A better understanding of structural,
biological and behavioral factors, including the chains of transmission by applying molecular methods and phylogenetic
analysis of HIV-1 sequences could improve the efficient targeting of HIV prevention efforts.
A group that has not yet benefitted from these global and regional HIV trends is young women. Adolescent girls and
young women acquire HIV infection 5-7 years before men. This age-sex difference in HIV acquisition is a major driver
of  new  HIV  infections  despite  unprecedentedly  high  HIV  prevalence.  There  remains  a  knowledge  gap  in  women
initiated prevention technologies and interventions for this critical group of young women. The potential for ARV based
vaginal  microbicides,  PrEP  and  passive  immunity  offer  hope  for  young  women  but  are  several  years  away.  It  is
therefore crucial that clinical trials include adolescent women towards an AIDS-free generation.
Sub-Saharan Africa contributes disproportionately to the number of HIV/AIDS deaths. ART guidelines have been
changing to increase coverage of those infected but, despite large numbers on treatment, death rates remain high. A
large  number  of  people  remain  unaware  of  their  HIV status  and  therefore  fail  to  be  adequately  linked  to  care  and
treatment programs. Prevention benefits of treatment will require large numbers of men to be tested and initiated on
treatment - men who are not typical users of health services and less likely to initiate treatment.
Notwithstanding gaps in our efforts, the confluence of science and knowledge of the HIV epidemic marks one of the
most  optimistic  moments  in  our  response.  What  we do  collectively  will  define  what  impact  we make on  epidemic
control even as we continue our quest for a vaccine and cure for eradicating and ending the HIV epidemic.
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